Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label pazopanib monotherapy in progressive advanced or metastatic neuroendocrine tumors
2010-020749-28Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in apudoma (NET), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Clinical benefit rate at 6 months. Started Oct 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2010-020749-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020749-28.